Home / Peptides / Cagrilintide

Cagrilintide (CagriSema) Dosage Chart and Schedule

Not approved

Long-acting amylin analogue from Novo Nordisk, paired with semaglutide as CagriSema. Not approved yet.

Also called: NN9838, CagriSema

Regulatory status (US)

Not approved. Novo Nordisk filed CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg weekly) with the FDA in December 2025 and expects a decision in late 2026; as of November 15, 2026 it was still not approved. Cagrilintide on its own is investigational and is not on any compounding list.

What it is

A long-acting, once-weekly analogue of amylin, a hormone released with insulin that slows stomach emptying and increases fullness.

Doses studied

TrialWeekly doseResult
Phase 2, cagrilintide alone0.3 to 4.5 mg6.0% to 10.8% weight loss at 26 weeks
REDEFINE 1, CagriSema2.4 mg cagrilintide + 2.4 mg semaglutide20.4% at 68 weeks

Trial doses, not a label or a recommendation. The escalation schedule used in REDEFINE 1 is not shown here because we could not confirm it.

Cagrilintide reconstitution calculator

Enter your vial and your prescribed dose to see the units on a U-100 syringe.

–
Concentration–
Per 1 unit (0.01 mL)–
Volume per dose–
Doses per vial–

What human studies show

Safety

Compare

Questions

Is Cagrilintide FDA-approved?
Not approved. Novo Nordisk filed CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg weekly) with the FDA in December 2025 and expects a decision in late 2026; as of November 15, 2026 it was still not approved. Cagrilintide on its own is investigational and is not on any compounding list.
What dose of Cagrilintide has been studied?
Phase 2, cagrilintide alone: 0.3 to 4.5 mg: 6.0% to 10.8% weight loss at 26 weeks; REDEFINE 1, CagriSema: 2.4 mg cagrilintide + 2.4 mg semaglutide: 20.4% at 68 weeks. Trial doses, not a label or a recommendation. The escalation schedule used in REDEFINE 1 is not shown here because we could not confirm it.
How many units is my Cagrilintide dose?
Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.

Related

Retatrutide

Weekly GIP, GLP-1 and glucagon agonist from Lilly. Phase 3, not approved; up to 28% weight loss in trials.

Sources

  1. Lau et al. Once-weekly cagrilintide for weight management: phase 2 trial. Lancet 2021
  2. Garvey et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). NEJM 2025
  3. Novo Nordisk company announcement on CagriSema (Nov 2026)
  4. FDA 510(k) K212499: BD insulin syringes for U-100 insulin

Last checked 2026-11-16. How we pick and check sources: methodology.